These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21417818)

  • 1. Maximizing the outcome of early ADMET models: strategies to win the drug-hunting battles?
    Wang J; Collis A
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):381-6. PubMed ID: 21417818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in physicochemical and ADMET profiling in drug discovery.
    Wang J; Skolnik S
    Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitigating permeability-mediated risks in drug discovery.
    Wang J; Skolnik S
    Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):171-87. PubMed ID: 20064074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent development in high-throughput bioanalytical support for in vitro ADMET profiling.
    Shou WZ; Zhang J
    Expert Opin Drug Metab Toxicol; 2010 Mar; 6(3):321-36. PubMed ID: 20163321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Building predictive ADMET models for early decisions in drug discovery.
    Penzotti JE; Landrum GA; Putta S
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):49-61. PubMed ID: 14982148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond profiling: using ADMET models to guide decisions.
    Segall M; Champness E; Obrezanova O; Leeding C
    Chem Biodivers; 2009 Nov; 6(11):2144-51. PubMed ID: 19937845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive assessment of ADMET risks in drug discovery.
    Wang J
    Curr Pharm Des; 2009; 15(19):2195-219. PubMed ID: 19601823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico ADMET prediction: recent advances, current challenges and future trends.
    Cheng F; Li W; Liu G; Tang Y
    Curr Top Med Chem; 2013; 13(11):1273-89. PubMed ID: 23675935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving compound quality through in vitro and in silico physicochemical profiling.
    van de Waterbeemd H
    Chem Biodivers; 2009 Nov; 6(11):1760-6. PubMed ID: 19937820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADMET--Fifth Annual SMi Conference.
    Comer JE
    IDrugs; 2010 Sep; 13(9):610-4. PubMed ID: 20799141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward in silico structure-based ADMET prediction in drug discovery.
    Moroy G; Martiny VY; Vayer P; Villoutreix BO; Miteva MA
    Drug Discov Today; 2012 Jan; 17(1-2):44-55. PubMed ID: 22056716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular models for ADMET predictions and evaluation of drug-drug interactions.
    Riley RJ; Kenna JG
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):86-99. PubMed ID: 14982152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of drug safety testing: expanding the view and narrowing the focus.
    Stevens JL; Baker TK
    Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategic applications of toxicogenomics in early drug discovery.
    Ryan TP; Stevens JL; Thomas CE
    Curr Opin Pharmacol; 2008 Oct; 8(5):654-60. PubMed ID: 18760379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
    Nassar AE; Talaat RE; Kamel AM
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADMET considerations for phosphodiesterase-5 inhibitors.
    Rezvanfar MA; Rahimi HR; Abdollahi M
    Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1231-45. PubMed ID: 22769968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing paradigm for prediction of development-limiting barriers and human drug toxicity.
    Sasseville VG; Lane JH; Kadambi VJ; Bouchard P; Lee FW; Balani SK; Miwa GT; Smith PF; Alden CL
    Chem Biol Interact; 2004 Nov; 150(1):9-25. PubMed ID: 15522258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.